References
- Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–115.
- Mutimer D, Aghemo A, Diepolder H, et al. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.
- WHO: guidelines for screening care and treatment of persons with chronic hepatitis C infection. Updated version 2016, ISBN 978 92 4 154961 5. [ cited 2019 Jan]. Available from: https://apps.who.int/iris/bitstream/handle/10665/205035/9789241549615_eng.pdf;jsessionid=7DD81A30D03F26C35EA93715F21FE322?sequence=1.
- Gupta E, Bajpai M, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J Transfus Sci. 2014;8:19–25.
- Backus LI, Belperio PS. Comparative effectiveness of ledispavir/sofosbuvir ± ribavirin vs. obmitasvir/paritaprevir/ritonavir + dasabuvir± ribavirivn in 6961 genotype 1 patients treated in routine medical practice. Aliment Pharmacol Ther. 2016;44:400–410.
- Jacobson IM, Lawitz E, Kwo PY. Safety and efficacy of elbasavir/gazoprevir in patients with hepatitis C virusinfection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017;152:1372–1382.
- Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrenstavir for 8 or 12 weeks in patients with hepatitis 2, 4, 5 or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417–426.
- WHO: guidelines on hepatitis B and C testing 2017. ISBN 978-92-4-154998-1. [ cited 2019 Jan]. Available from: https://apps.who.int/iris/bitstream/handle/10665/254621/9789241549981-eng.pdf?sequence=1.
- Pharmacotherapeutic guideline for treatment of gastro-intestinal diseases/28.01.2016. [ cited 2018 Feb]. Available from: http://ncpr.bg/.
- Antonov KA. Diagnostic and treatment of chronic HC infection in Bulgaria – past and present. Clujul Med. 2010;LXXXIII-nr.1:13–15.
- Dimitrova M, Pavlov K, Mitov K, et al. Chornic Hepatitis C-related cirrhosis hospitalization cost analysis in Bulgaria. Front Med (Lausanne). 2017;4. DOI:10.3389/fmed.2017.00125.
- Kotzev I, Ivanova I. Hepatitis C. GP News. 2011;5.
- Dimitrova M, Kamusheva M, Mitov K, et al. Screening and diagnosis of chronic HCV infection in Bulgaria: a review of the current practice. Biomed Res. 2018;29:13.
- WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
- Ordinance for the regulation and registration of the prices of the medicinal products/2013.
- National Statistics Institute. [ cited 2019 Feb]. Available from: www.nsi.bg.
- Bulgarian National Bank. [ cited 2019 Mar]. Available from: www.bnb.bg.
- Bertam MY, Lauer JA, Joncheere KD, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94:925–930.
- Clinical evidence-based guideline for breast cancer. MORE 2013. [cited 2019 Mar]. Available from: http://www.sbaloncology.bg/bg/science-and-research/library/more2013.htmlhttp://www.mh.government.bg/media/filer_public/2019/02/15/pms_ceni_tarifa_upnscrlp_11022019.pdf.
- Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013 Feb;33(Suppl 1):93–104.
- Cenderello G, Taramasso L, Marra D, et al. HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation. Expert Rev Pharmacoecon Outcomes Res. 2019;19:2.
- Coward S, Leggett L, Kaplan GG, et al. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations. BMJ Open. 2016;6(9):e011821.
- Caballería L, Pera G, Bernad J, et al. Strategies for the detection of hepatitis C viral infection in the general population. Rev Clin Esp (Barc). 2014 Jun-Jul;214(5): 242–246.
- Wong WWL, Tu HA, Feld JJ, et al. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ. 2015;187(3):E110–E121.
- Ruggeri M, Coretti S, Gasbarrini A, et al. Economic assessment of an anti-HCV screening program in Italy. Value Health. 2013;16(6):965–972.
- WHO: guidelines for the screening, care and treatment of persons with hepatitis C infection 2014. [cited 2019 Feb]. Available from: https://apps.who.int/iris/bitstream/handle/10665/111747/9789241548755_eng.pdf?sequence=1.